Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Tranzyme, Inc.
Tranzyme shares plunged over 75% Thursday after a preliminary analysis showed
that their gastroparesis drug, TZP-102, failed to meet its primary efficacy endpoint.
Going forward ... (see research report)
Subscribe to News Feeds